{
    "clinical_study": {
        "@rank": "74061", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute\n      heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal,\n      reduces opiate craving, and is safe at doses required to produce the above effects."
        }, 
        "brief_title": "Effects of Dynorphin 1-13 on Heroin Addiction - 1", 
        "completion_date": {
            "#text": "March 1997", 
            "@type": "Actual"
        }, 
        "condition": [
            "Opioid-Related Disorders", 
            "Substance Withdrawal Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heroin Dependence", 
                "Opioid-Related Disorders", 
                "Substance Withdrawal Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on\n      heroin withdrawal in human opiate addicts"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        opiate addict between the ages of 18-55\n\n        Exclusion Criteria:\n\n        Regular abuse of other drugs, unstable medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000244", 
            "org_study_id": "NIDA-08067-1", 
            "secondary_id": [
                "R01DA008067", 
                "R01-08067-1"
            ]
        }, 
        "intervention": {
            "intervention_name": "Dynorphin 1 - 13", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dynorphins"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55415"
                }, 
                "name": "U of Minnesota School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Effects of Dynorphin 1-13 on Heroin Addiction", 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Paul Pentel, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 1997", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Craving scale"
        }, 
        "reference": {
            "PMID": "9676891", 
            "citation": "Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, Pentel PR. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl). 1998 Jun;137(4):326-32."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000244"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1994", 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }, 
    "geocoordinates": {
        "U of Minnesota School of Medicine": "44.98 -93.264"
    }
}